(88 days)
Bioteque A.V. Fistula Needle is used during hemodialysis. It's a part of accessory of extracorporeal system for treatment of renal failure. A.V. Fistula Needle applied on the access site of patient's vessel to obtain blood flow adequate to pass through the dialyses, and the reinfusion of dialysed blood back to patient via the fistula needle during hemodialysis.
Bioteque A.V. Fistula Needle Set consist of the following 6 major components: the stainless needle, protector cap for needle, the plastic butterfly wing, the PVC tubing, the female luer, the cap for female luer. These 6 major components assembled together as A.V. Fistula Needle Set for use during hemodialysis procedures. Various models of needle size manufactured such as 14 gauge, 15 gauge, 16 gauge.
The provided document is a 510(k) summary for the BIOTEQUE A.V. FISTULA NEEDLE SET. This submission primarily focuses on demonstrating substantial equivalence to a predicate device, rather than presenting a performance study with detailed acceptance criteria and testing results as would be typical for more complex devices or novel technologies.
Here's an analysis based on the provided text, addressing the requested information:
1. Table of Acceptance Criteria and Reported Device Performance
The submission does not explicitly list quantitative acceptance criteria or specific performance metrics in a table format with numerical results. Instead, it states that the device "conforms to applicable standards." The acceptance criteria are implicitly tied to compliance with these standards and demonstrating similar technological characteristics to the predicate device.
| Acceptance Criteria (Implicit) | Reported Device Performance (Summary) |
|---|---|
| Physical specifications | Conforms to applicable standards (including ISO 10993 series, ISO 11607-1, ISO 11135, USP Pyrogenic standards & related standards). Acknowledged to have the same intended use and similar technological characteristics as the predicate device (TERUMO AV FISTULA NEEDLE SET K891062). |
| Chemical specifications | Conforms to applicable standards (including ISO 10993 series, ISO 11607-1, ISO 11135, USP Pyrogenic standards & related standards). Acknowledged to have the same intended use and similar technological characteristics as the predicate device (TERUMO AV FISTULA NEEDLE SET K891062). |
| Biological specifications | Conforms to applicable standards (including ISO 10993 series, ISO 11607-1, ISO 11135, USP Pyrogenic standards & related standards). Specifically mentions USP Pyrogenic standards. Acknowledged to have the same intended use and similar technological characteristics as the predicate device (TERUMO AV FISTULA NEEDLE SET K891062). |
| Performance specifications | Conforms to applicable standards (including ISO 10993 series, ISO 11607-1, ISO 11135, USP Pyrogenic standards & related standards). Bench testing demonstrated that differences in technological characteristics do not raise new questions of safety or effectiveness. Acknowledged to have the same intended use and similar technological characteristics as the predicate device (TERUMO AV FISTULA NEEDLE SET K891062). |
| Sterilization specifications | Conforms to applicable standards (including ISO 10993 series, ISO 11607-1, ISO 11135, USP Pyrogenic standards & related standards). Acknowledged to have the same intended use and similar technological characteristics as the predicate device (TERUMO AV FISTULA NEEDLE SET K891062). |
| Substantial Equivalence | Concluded to be substantially equivalent to the TERUMO AV FISTULA NEEDLE SET (K891062). |
2. Sample Size Used for the Test Set and Data Provenance
The document mentions "bench testing contained in this submission" but does not specify the sample size for any test sets used. The nature of the device (a medical needle for hemodialysis) suggests bench testing primarily, not clinical trials with patient data. Therefore, questions of retrospective/prospective data or country of origin for a clinical test set are not applicable here. The testing would have been conducted in a laboratory setting.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts
This information is not applicable and not provided for this type of device and submission. The "ground truth" for mechanical and biological safety of an A.V. fistula needle is established by adherence to recognized international and national standards (e.g., ISO, USP) and engineering principles, not through expert consensus on diagnostic images or clinical outcomes in the same way as, for example, an AI diagnostic tool.
4. Adjudication Method for the Test Set
This information is not applicable and not provided. Adjudication methods (like 2+1, 3+1) are typically used in clinical studies or studies involving subjective human interpretation (e.g., image reading) to establish a consensus ground truth. The tests mentioned (physical, chemical, biological, sterilization, performance) are objective laboratory/bench tests, not requiring human adjudication in this context.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done
No, an MRMC comparative effectiveness study was not done. This type of study is relevant for diagnostic or AI-assisted devices where human readers interpret medical images or data. The BIOTEQUE A.V. FISTULA NEEDLE SET is a physical medical device (a needle), and its effectiveness is determined by its functional performance and safety according to engineering and biological standards, not by human reader performance.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Study Was Done
This question is not applicable as the device is a physical medical needle, not an algorithm or AI system.
7. The Type of Ground Truth Used
The "ground truth" for the device's performance and safety is established through adherence to recognized industry standards and laboratory testing protocols. These standards (e.g., ISO 10993 series for biocompatibility, ISO 11607-1 for packaging, ISO 11135 for sterilization, USP Pyrogenic standards) define the acceptable limits and methods for evaluating the physical, chemical, biological, and performance characteristics of such devices. Therefore, the ground truth is based on objective measurements against established standards, not expert consensus, pathology, or outcomes data in the sense typically understood for diagnostic or interventional devices.
8. The Sample Size for the Training Set
This information is not applicable and not provided. The device is a physical medical device, not an AI or machine learning model that requires a training set.
9. How the Ground Truth for the Training Set Was Established
This information is not applicable as there is no training set for this type of device.
§ 876.5540 Blood access device and accessories.
(a)
Identification. A blood access device and accessories is a device intended to provide access to a patient's blood for hemodialysis or other chronic uses. When used in hemodialysis, it is part of an artificial kidney system for the treatment of patients with renal failure or toxemic conditions and provides access to a patient's blood for hemodialysis. The device includes implanted blood access devices, nonimplanted blood access devices, and accessories for both the implanted and nonimplanted blood access devices.(1) The implanted blood access device is a prescription device and consists of various flexible or rigid tubes, such as catheters, or cannulae, which are surgically implanted in appropriate blood vessels, may come through the skin, and are intended to remain in the body for 30 days or more. This generic type of device includes various catheters, shunts, and connectors specifically designed to provide access to blood. Examples include single and double lumen catheters with cuff(s), fully subcutaneous port-catheter systems, and A-V shunt cannulae (with vessel tips). The implanted blood access device may also contain coatings or additives which may provide additional functionality to the device.
(2) The nonimplanted blood access device consists of various flexible or rigid tubes, such as catheters, cannulae or hollow needles, which are inserted into appropriate blood vessels or a vascular graft prosthesis (§§ 870.3450 and 870.3460), and are intended to remain in the body for less than 30 days. This generic type of device includes fistula needles, the single needle dialysis set (coaxial flow needle), and the single needle dialysis set (alternating flow needle).
(3) Accessories common to either type include the shunt adaptor, cannula clamp, shunt connector, shunt stabilizer, vessel dilator, disconnect forceps, shunt guard, crimp plier, tube plier, crimp ring, joint ring, fistula adaptor, and declotting tray (including contents).
(b)
Classification. (1) Class II (special controls) for the implanted blood access device. The special controls for this device are:(i) Components of the device that come into human contact must be demonstrated to be biocompatible. Material names and specific designation numbers must be provided.
(ii) Performance data must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested:
(A) Pressure versus flow rates for both arterial and venous lumens, from the minimum flow rate to the maximum flow rate in 100 milliliter per minute increments, must be established. The fluid and its viscosity used during testing must be stated.
(B) Recirculation rates for both forward and reverse flow configurations must be established, along with the protocol used to perform the assay, which must be provided.
(C) Priming volumes must be established.
(D) Tensile testing of joints and materials must be conducted. The minimum acceptance criteria must be adequate for its intended use.
(E) Air leakage testing and liquid leakage testing must be conducted.
(F) Testing of the repeated clamping of the extensions of the catheter that simulates use over the life of the device must be conducted, and retested for leakage.
(G) Mechanical hemolysis testing must be conducted for new or altered device designs that affect the blood flow pattern.
(H) Chemical tolerance of the device to repeated exposure to commonly used disinfection agents must be established.
(iii) Performance data must demonstrate the sterility of the device.
(iv) Performance data must support the shelf life of the device for continued sterility, package integrity, and functionality over the requested shelf life that must include tensile, repeated clamping, and leakage testing.
(v) Labeling of implanted blood access devices for hemodialysis must include the following:
(A) Labeling must provide arterial and venous pressure versus flow rates, either in tabular or graphical format. The fluid and its viscosity used during testing must be stated.
(B) Labeling must specify the forward and reverse recirculation rates.
(C) Labeling must provide the arterial and venous priming volumes.
(D) Labeling must specify an expiration date.
(E) Labeling must identify any disinfecting agents that cannot be used to clean any components of the device.
(F) Any contraindicated disinfecting agents due to material incompatibility must be identified by printing a warning on the catheter. Alternatively, contraindicated disinfecting agents must be identified by a label affixed to the patient's medical record and with written instructions provided directly to the patient.
(G) Labeling must include a patient implant card.
(H) The labeling must contain comprehensive instructions for the following:
(
1 ) Preparation and insertion of the device, including recommended site of insertion, method of insertion, and a reference on the proper location for tip placement;(
2 ) Proper care and maintenance of the device and device exit site;(
3 ) Removal of the device;(
4 ) Anticoagulation;(
5 ) Management of obstruction and thrombus formation; and(
6 ) Qualifications for clinical providers performing the insertion, maintenance, and removal of the devices.(vi) In addition to Special Controls in paragraphs (b)(1)(i) through (v) of this section, implanted blood access devices that include subcutaneous ports must include the following:
(A) Labeling must include the recommended type of needle for access as well as detailed instructions for care and maintenance of the port, subcutaneous pocket, and skin overlying the port.
(B) Performance testing must include results on repeated use of the ports that simulates use over the intended life of the device.
(C) Clinical performance testing must demonstrate safe and effective use and capture any adverse events observed during clinical use.
(vii) In addition to Special Controls in paragraphs (b)(1)(i) through (v) of this section, implanted blood access devices with coatings or additives must include the following:
(A) A description and material characterization of the coating or additive material, the purpose of the coating or additive, duration of effectiveness, and how and where the coating is applied.
(B) An identification in the labeling of any coatings or additives and a summary of the results of performance testing for any coating or material with special characteristics, such as decreased thrombus formation or antimicrobial properties.
(C) A Warning Statement in the labeling for potential allergic reactions including anaphylaxis if the coating or additive contains known allergens.
(D) Performance data must demonstrate efficacy of the coating or additive and the duration of effectiveness.
(viii) The following must be included for A-V shunt cannulae (with vessel tips):
(A) The device must comply with Special Controls in paragraphs (b)(1)(i) through (v) of this section with the exception of paragraphs (b)(1)(ii)(B), (b)(1)(ii)(C), (b)(1)(v)(B), and (b)(1)(v)(C), which do not apply.
(B) Labeling must include Warning Statements to address the potential for vascular access steal syndrome, arterial stenosis, arterial thrombosis, and hemorrhage including exsanguination given that the device accesses the arterial circulation.
(C) Clinical performance testing must demonstrate safe and effective use and capture any adverse events observed during clinical use.
(2) Class II (performance standards) for the nonimplanted blood access device.
(3) Class II (performance standards) for accessories for both the implanted and the nonimplanted blood access devices not listed in paragraph (b)(4) of this section.
(4) Class I for the cannula clamp, disconnect forceps, crimp plier, tube plier, crimp ring, and joint ring, accessories for both the implanted and nonimplanted blood access device. The devices subject to this paragraph (b)(4) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.